An inverse docking approach for identifying new potential anti-cancer targets

Journal of Molecular Graphics and Modelling

Volumn 29, Issue 6, 2011, Pages 795-799

  Grinter, Sam Z ^a,b   Liang, Yayun ^a,b   Huang, Sheng You ^a,b,c   Hyder, Salman M ^a,b   Zou, Xiaoqin ^a,b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c University of Missouri   (United States)

Author keywords

In silico screening; Inverse docking; Molecular docking; Protein ligand interactions

Indexed keywords

ANTI-CANCER THERAPIES; APOPTOSIS; BINDING AFFINITIES; BREAST CANCER CELLS; CANCER CELL GROWTH; CANCER CELLS; COMPUTATIONALLY EFFICIENT; HUMAN BREAST CANCER CELLS; HUMAN PROTEINS; IN-SILICO; IN-SILICO SCREENING; INVERSE DOCKING; MOLECULAR DOCKING; OXIDOSQUALENE CYCLASES; PROTEIN-LIGAND INTERACTIONS; RECEPTOR TARGETS; SMALL MOLECULES; SYNTHETIC PATHWAYS; TUMOR SUPPRESSORS; VALIDATION STUDY;

BINDING ENERGY; CELL DEATH; DATA PRIVACY; GROWTH KINETICS; LIGANDS; MOLECULAR MODELING; NETWORK SECURITY; PROTEINS;

DISEASES;

ANTINEOPLASTIC AGENT; CHOLESTEROL; DNA; LANOSTEROL SYNTHASE; PRIMA 1 PROTEIN; PROTEIN; PROTEIN P53; RO 48 8071; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CHOLESTEROL SYNTHESIS; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; BENZOPHENONES; BICYCLO COMPOUNDS, HETEROCYCLIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; DNA; DRUG DISCOVERY; ENZYME INHIBITORS; FEMALE; HUMANS; INTRAMOLECULAR TRANSFERASES; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79953286431     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2011.01.002     Document Type: Article

References (35)

1. Y.Z. Chen, and D.G. Zhi Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule Proteins 43 2001 217 226
2. Q.T. Do, I. Renimel, P. Andre, C. Lugnier, C.D. Muller, and P. Bernard Reverse pharmacognosy: application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin Curr. Drug Discov. Technol. 2 2005 161 167 (Pubitemid 41242961)
3. P. Muller, G. Lena, E. Boilard, S. Bezzine, G. Lambeau, G. Guichard, and D. Rognan In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors J. Med. Chem. 49 2006 6768 6778 (Pubitemid 44749744)
4. S. Zahler, S. Tietze, F. Totzke, M. Kubbutat, L. Meijer, A.M. Vollmar, and J. Apostolakis Inverse in silico screening for identification of kinase inhibitor targets Chem. Biol. 14 2007 1207 1214 (Pubitemid 350102244)
5. M. Schapira, R. Abagyan, and M. Totrov Nuclear hormone receptor targeted virtual screening J. Med. Chem. 46 2003 3045 3059 (Pubitemid 36775926)
6. J.M. Rollinger Accessing target information by virtual parallel screening the impact on natural product research Phytochem. Lett. 2 2009 53 58
7. C. Bissantz, A. Logean, and D. Rognan High-throughput modeling of human g-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening J. Chem. Inf. Comput. Sci. 44 2004 1162 1176
8. S.-Y. Huang, and X. Zou An iterative knowledge-based scoring function to predict protein-ligand interactions. I: derivation of interaction potentials J. Comput. Chem. 27 2006 1865 1875
9. S.-Y. Huang, and X. Zou An iterative knowledge-based scoring function to predict protein-ligand interactions. II: validation of the scoring function J. Comput. Chem. 27 2006 1876 1882 (Pubitemid 44672569)
10. V.J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K.G. Wiman, and G. Selivanova Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat. Med. 8 2002 282 288 (Pubitemid 34250107)
11. Y. Liang, J. Wu, G.M. Stancel, and S.M. Hyder p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells J. Steroid Biochem. Mol. Biol. 93 2005 173 182 (Pubitemid 40602490)
12. Y. Liang, C. Besch-Williford, I. Benakanakere, and S.M. Hyder Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells Int. J. Oncol. 31 2007 777 784
13. Y. Liang, C. Besch-Williford, R.A. Brekken, and S.M. Hyder Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics Cancer Res. 67 2007 9929 9936 (Pubitemid 47621242)
14. T. Wang, K. Lee, A. Rehman, and S.S. Daoud PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax Biochem. Biophys. Res. Commun. 352 2007 203 212 (Pubitemid 44821115)
15. J.M.R. Lambert, P. Gorzov, D.B. Veprintsev, M. Söderqvist, D. Segerbäck, J. Bergman, A.R. Fersht, P. Hainaut, K.G. Wilman, and V.J.N. Bykov PRIMA-1 reactivates mutant p53 by covalent binding to the core domain Cancer Cell 15 2009 376 388
16. O.H. Morand, J. Aebi, P. Guerry, P.G. Hartman, U. Hennes, J. Himber, Y.H. Ji, S. Jolidon, and H. Lengsfeld Potent inhibitors of mammalian 2,3-oxidosqualene: lanosterol cyclase are orally active cholesterol lowering agents Atherosclerosis 109 1994 321 suppl.
17. A. Lenhart, D.J. Reinert, J.D. Aebi, H. Dehmlow, O.H. Morand, and G.E. Schulz Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene hopene cyclase J. Med. Chem. 46 2003 2083 2092 (Pubitemid 36583487)
18. A.M. Davidoff, B.J. Kerns, J.C. Pence, J.R. Marks, and J.D. Iglehart p53 alteration in all stages of breast cancer J. Surg. Oncol. 48 1991 260 267
19. Z. Gao, H. Li, H. Zhang, X. Liu, L. Kang, X. Luo, W. Zhu, K. Chen, X. Wang, and H. Jiang PDTD: a web-accessible protein database for drug target identification BMC Bioinform. 9 104 2008 1 7
20. S.-Y. Huang, and X. Zou Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking Proteins 66 2007 399 421 (Pubitemid 46053470)
21. S.-Y. Huang, and X. Zou Efficient molecular docking of NMR structures: application to HIV-1 protease Protein Sci. 16 2007 43 51 (Pubitemid 46036497)
22. S.-Y. Huang, and X. Zou Inclusion of solvation and entropy in the knowledge-based scoring function for protein-ligand interactions J. Chem. Inf. Model. 50 2010 262 273
23. T.J. Ewing, S. Makino, G.A. Skillman, and I.D. Kuntz DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases J. Comput. Aided Mol. Des. 15 2001 411 428 (Pubitemid 32452109)
24. I.D. Kuntz, J.M. Blaney, S.J. Oatley, R. Langridge, and T.E. Ferrin A geometric approach to macromolecule-ligand interactions J. Mol. Biol. 161 1982 269 288
25. S.F. Altschul, W. Gish, W. Miller, E.W. Myers, and D.J. Lipman Basic local alignment search tool J. Mol. Biol. 215 1990 403 410
26. L.V. Rubinstein, R.H. Shoemaker, and K.D. Paull Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines J. Natl. Cancer Inst. 82 1990 1113 1118 (Pubitemid 20213251)
27. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112 (Pubitemid 20213250)
28. Y. Liang, and S.M. Hyder Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects Endocrinology 146 2005 3632 3641 (Pubitemid 41058135)
29. Y. Liang, R.A. Brekken, and S.M. Hyder Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones Endocr. Relat. Cancer 13 2006 905 919 (Pubitemid 44763266)
30. R. Thoma, T. Schulz-Gasch, B. D'Arcy, J. Benz, J. Aebi, H. Dehmlow, M. Hennig, M. Stihle, and A. Ruf: Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase Nature 432 2004 118 220
31. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The protein data bank Nucleic Acids Res. 28 2000 235 242 (Pubitemid 30047768)
32. O.H. Morand, J.D. Aebi, H. Dehmlow, Y.H. Ji, N. Gains, H. Lengsfeld, and J. Himber Ro 48-8.071, a new 2,3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin J. Lipid Res. 38 1997 373 390 (Pubitemid 27118049)
33. E.C. Meng, B.K. Shoichet, and I.D. Kuntz Automated docking with grid-based energy approach to macromolecule-ligand interactions J. Comput. Chem. 13 1992 505 524
34. P.T. Lang, S.R. Brozell, S. Mukherjee, E.T. Pettersen, E.C. Meng, V. Thomas, R.C. Rizzo, D.A. Case, T.L. James, and I.D. Kuntz DOCK 6 combining techniques to model RNA-small molecule complexes RNA 15 2009 1219 1230
35. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera a visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612